CURED Co., Ltd. announced a private placement of 42,000 shares at ¥3,800 per share for gross proceeds of ¥159,600,000 on April 20, 2016. The transaction will include participation from new investors, Immuno-Biological Laboratories Co., Ltd. and Trans Genic, Inc. for 21,000 shares each. On closing, each of the investors will hold 7.6% stake in the company.

As part of the transaction, the investors will acquire 15.2% stake in the company. The transaction is expected to close on May 11, 2016. The transaction was approved by the directors of Immuno-Biological Laboratories Co., Ltd. on the same date.